Beam Therapeutics Inc. (BEAM) Income Statement
BEAM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBEAM revenue and net income
Where BEAM's revenue goes
2025Each bar shows an amount and its share of revenue. BEAM kept −57.2% of revenue as net income.
BEAM profit margins
BEAM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +120.0% | +31.9% | +466.3% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BEAM quarterly EPS vs estimates
Beam Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 3, 2026 (estimate $-1.16).
BEAM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24,000 | $18,000 | $0 | $0 |
| Cost of revenue | $22.3M | $367.6M | $437.4M | $311.6M | $232.1M | $103.2M | $54.6M | $33.9M | $11,000 |
| Gross profit | $117.4M | −$304.0M | $377.7M | −$250.7M | −$180.3M | −$103.2M | −$54.6M | −$33.9M | −$11,000 |
| Research & development | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $103.2M | $54.6M | $33.9M | $5.9M |
| Sales, general & admin | $113.8M | $111.5M | $116.8M | $87.8M | $57.2M | $29.6M | $20.6M | $11.9M | $2.0M |
| Total operating expenses | $501.1M | $111.5M | $554.2M | $87.8M | $212.2M | $29.6M | $20.6M | $11.9M | $8.6M |
| Operating income | −$383.7M | −$415.6M | −$176.5M | −$338.5M | −$392.5M | −$132.8M | −$75.2M | −$45.7M | −$8.6M |
| Interest income | — | — | — | — | — | — | $2.5M | $292,000 | — |
| Interest expense | $43.7M | $49.1M | $46.7M | $15.3M | $9,000 | $1.6M | $187,000 | $0 | $0 |
| Income before taxes | −$80.0M | −$376.7M | −$131.2M | −$285.7M | −$370.6M | −$194.6M | −$78.3M | −$116.7M | −$8.7M |
| Income taxes | — | $39,000 | $1.4M | $3.4M | −$29.3M | $61.8M | $116,000 | −$71.0M | $500,000 |
| Net income | −$80.0M | −$376.7M | −$132.5M | −$289.1M | −$370.6M | −$194.6M | −$78.3M | −$115.3M | −$8.7M |
| EBITDA | −$14.0M | −$354.8M | −$111.1M | −$271.5M | −$230.1M | −$128.0M | −$71.7M | −$45.1M | −$8.6M |
| EPS (diluted) | −$1.01 | −$4.58 | −$1.90 | −$4.13 | −$5.95 | −$4.10 | −$6.36 | −$3.28 | — |
| Gross margin | 84.0% | −478.7% | 100.0% | −411.5% | −347.8% | −429,812.5% | −303,338.9% | — | — |
| Operating margin | −274.6% | −654.3% | −46.7% | −555.6% | −757.0% | −553,166.7% | −417,522.2% | — | — |
| Net margin | −57.2% | −593.1% | −35.1% | −474.5% | −714.9% | −810,800.0% | −435,144.4% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490,000 | $31.7M | $114.1M | $9.7M | $8.5M | $7.5M | $30.1M | $14.3M | $11.8M | $7.4M | $316.2M | $17.2M |
| Cost of revenue | $0 | $11.1M | $5.7M | $109.8M | $101.8M | $98.8M | $101.4M | $94.3M | $87.0M | $84.8M | $140.1M | $100.0M |
| Gross profit | $490,000 | $31.7M | $114.1M | $9.7M | −$93.3M | −$91.3M | −$71.4M | −$80.0M | −$75.3M | −$77.4M | $176.1M | −$82.9M |
| Research & development | $95.1M | $104.5M | $99.3M | $109.8M | $101.8M | $98.8M | $101.4M | $94.3M | $87.0M | $84.8M | $140.1M | $100.0M |
| Sales, general & admin | $31.9M | $34.4M | $32.3M | $26.7M | $26.9M | $27.9M | $28.7M | $26.5M | $29.6M | $26.7M | $43.3M | $25.4M |
| Total operating expenses | $127.0M | $139.0M | $131.6M | $136.5M | $26.9M | $27.9M | $28.7M | $26.5M | $29.6M | $26.7M | $43.3M | $25.4M |
| Operating income | −$126.6M | −$107.2M | −$17.4M | −$126.8M | −$120.2M | −$119.3M | −$100.0M | −$106.5M | −$104.9M | −$104.1M | $132.9M | −$108.3M |
| Interest income | — | — | — | — | — | — | — | $12.1M | — | — | — | $12.7M |
| Interest expense | $7.5M | $9.9M | $10.6M | $10.9M | $12.3M | — | — | $12.1M | $14.2M | — | $12.1M | $12.7M |
| Income before taxes | −$122.7M | −$94.3M | $244.3M | −$112.7M | −$102.3M | −$109.3M | −$90.4M | −$96.7M | −$91.0M | −$98.7M | $144.2M | −$96.1M |
| Income taxes | — | — | — | — | — | — | — | −$5.5M | $39,000 | $5.4M | $1.4M | −$17.4M |
| Net income | −$122.7M | −$94.3M | $244.3M | −$112.7M | −$102.3M | −$109.3M | −$90.4M | −$96.7M | −$91.1M | −$98.7M | $142.8M | −$96.1M |
| EBITDA | −$117.3M | −$88.7M | $250.0M | −$107.2M | −$96.8M | −$103.7M | −$84.9M | −$91.2M | −$85.4M | −$93.2M | $149.5M | −$90.9M |
| EPS (diluted) | −$1.18 | −$0.91 | $2.33 | −$1.10 | −$1.00 | −$1.24 | −$1.09 | −$1.17 | −$1.11 | −$1.21 | $1.73 | −$1.22 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | −1,102.0% | −1,222.8% | −237.4% | −560.6% | −639.4% | −1,044.6% | 55.7% | −481.9% |
| Operating margin | −25,827.1% | −337.8% | −15.3% | −1,307.6% | −1,419.2% | −1,596.9% | −332.7% | −746.4% | −891.1% | −1,405.3% | 42.0% | −629.7% |
| Net margin | −25,036.3% | −297.2% | 214.1% | −1,162.4% | −1,208.3% | −1,462.8% | −300.5% | −677.5% | −773.5% | −1,331.6% | 45.2% | −558.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BEAM's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BEAM financial results
In fiscal year 2025 (ended December 31, 2025), Beam Therapeutics reported revenue of $139.7 million, up 120.0% from the year before. It had a net loss of $80.0 million, a net profit margin of −57.2%. Diluted earnings per share came to −$1.01. Over five years revenue grew at an average rate of 466.3% a year.
See the BEAM stock overview for the latest quote and news, or the BEAM chart for price history and technical indicators.
BEAM income statement FAQ
What is Beam Therapeutics's annual revenue?
Beam Therapeutics reported total revenue of $139.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 120.0% from $63.5 million the previous year.
Is Beam Therapeutics profitable?
No. Beam Therapeutics reported a net loss of $80.0 million in fiscal 2025, a net profit margin of −57.2%; its operating margin was −274.6%.
What is Beam Therapeutics's gross margin?
Beam Therapeutics's gross margin was 84.0% in fiscal 2025: for every $100 of revenue, Beam Therapeutics kept $84 after the direct cost of its products and services.
How much does Beam Therapeutics spend on research and development?
Beam Therapeutics spent $409.6 million on research and development in fiscal 2025, 293.1% of revenue.
How fast is Beam Therapeutics growing?
Revenue grew 466.3% a year on average over the last five fiscal years, from $0.0 million to $139.7 million.
What are Beam Therapeutics's earnings per share?
Beam Therapeutics earned $-1.01 per diluted share in fiscal 2025, compared with $-4.58 a year earlier.
When will Beam Therapeutics report its next earnings?
Beam Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does Beam Therapeutics's fiscal year end?
Beam Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.